Super antibacterial ‘Tygacil’ continues to monopolization, succeeding in defending patent

Published: 2016-09-01 14:40:34

Updated: 2016-09-01 14:40:34

The domestic exclusive license of a Pfizer’s super antibacterial drug ‘Tygacil(tigecycline)’ is expected to be extended.

The substance patent of Tygacil was expired this May, but the company has blocked other generic companies using its valid composition patent expiring in 2026.

According to the industry on the 30^th, Penmix failed to challenge the Tygacil’s composition patent recently.

Penmi...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.